CUSIP: 87424L108
Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
14,910,168
-
Share change
-
-1,671,588
-
Total reported value
-
$12,107,000
-
Price per share
-
$0.81
-
Number of holders
-
26
-
Value change
-
-$1,557,935
-
Number of buys
-
12
-
Number of sells
-
28
Quarterly Holders Quick Answers
What is CUSIP 87424L108?
CUSIP 87424L108 identifies TLIS - TALIS BIOMEDICAL CORP - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2022
-
Previous quarter:
Q1 2022
Recent filing periods for CUSIP 87424L108:
Institutional Holders of TALIS BIOMEDICAL CORP - COM (TLIS) as of Q2 2022
As of 30 Jun 2022,
TALIS BIOMEDICAL CORP - COM (TLIS) was held by
26 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
14,910,168 shares.
The largest 10 holders included
BAKER BROS. ADVISORS LP, ArrowMark Colorado Holdings LLC, GREENLIGHT CAPITAL INC, VANGUARD GROUP INC, Newtyn Management, LLC, PRELUDE CAPITAL MANAGEMENT, LLC, MILLENNIUM MANAGEMENT LLC, MORGAN STANLEY, GEODE CAPITAL MANAGEMENT, LLC, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
26
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.